P Huangfu1, C Ugarte-Gil2, J Golub3, F Pearson1, J Critchley1. 1. Population Health Research Institute, St George's University of London, London, UK. 2. Facultad de Medicina Alberto Hurtado and Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD. 3. Centre for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Previous evidence synthesis has suggested diabetes mellitus (DM) worsens tuberculosis (TB) treatment outcomes. However, these reviews are limited by the number, robustness and conflicting results among the studies included. We conducted a systematic review to update earlier analyses and explore heterogeneity among studies. METHODS: MEDLINE, EMBASE, AIM, LILACS, IMEMR, IMSEAR and WPRIM were searched between 1 January 1980 and 23 July 2018 unrestricted by language or region. All cohort and case-control studies investigating the difference in TB treatment outcomes amongst TB-DM patients compared to those with TB alone were included. Two reviewers independently assessed titles, abstracts, and extracted data. Culture conversion at two/three months, all-cause mortality, treatment failure, relapse and multidrug-resistant TB (MDR-TB) were evaluated using random effects meta-analysis with generic inverse variance. Heterogeneity was explored using subgroup analyses and meta-regression. RESULTS: One hundred and four publications were identified. Sixty-four studies including 56 122 individuals with TB-DM and 243 035 with TB, reported on death. Some outcomes showed substantial heterogeneity between studies, which we could not fully explain, though confounding adjustment and country income level accounted for some of the differences. TB-DM patients had higher odds of death (OR 1.88, 95%CI 1.59-2.21) and relapse (OR 1.64, 95%CI 1.29-2.08) compared to TB patients. More limited evidence suggested TB-DM patients had double the risk of developing MDR-TB (OR 1.98, 95%CI 1.51-2.60). CONCLUSION: DM is associated with increased risks of poor TB treatment outcomes, particularly mortality, and may increase risk of developing primary MDR-TB. Cost-effectiveness of interventions to enhance TB-DM treatment should be assessed.
BACKGROUND: Previous evidence synthesis has suggested diabetes mellitus (DM) worsens tuberculosis (TB) treatment outcomes. However, these reviews are limited by the number, robustness and conflicting results among the studies included. We conducted a systematic review to update earlier analyses and explore heterogeneity among studies. METHODS: MEDLINE, EMBASE, AIM, LILACS, IMEMR, IMSEAR and WPRIM were searched between 1 January 1980 and 23 July 2018 unrestricted by language or region. All cohort and case-control studies investigating the difference in TB treatment outcomes amongst TB-DMpatients compared to those with TB alone were included. Two reviewers independently assessed titles, abstracts, and extracted data. Culture conversion at two/three months, all-cause mortality, treatment failure, relapse and multidrug-resistant TB (MDR-TB) were evaluated using random effects meta-analysis with generic inverse variance. Heterogeneity was explored using subgroup analyses and meta-regression. RESULTS: One hundred and four publications were identified. Sixty-four studies including 56 122 individuals with TB-DM and 243 035 with TB, reported on death. Some outcomes showed substantial heterogeneity between studies, which we could not fully explain, though confounding adjustment and country income level accounted for some of the differences. TB-DMpatients had higher odds of death (OR 1.88, 95%CI 1.59-2.21) and relapse (OR 1.64, 95%CI 1.29-2.08) compared to TB patients. More limited evidence suggested TB-DMpatients had double the risk of developing MDR-TB (OR 1.98, 95%CI 1.51-2.60). CONCLUSION:DM is associated with increased risks of poor TB treatment outcomes, particularly mortality, and may increase risk of developing primary MDR-TB. Cost-effectiveness of interventions to enhance TB-DM treatment should be assessed.
Authors: Willyhelmina Olomi; Irene Andia Biraro; Kajiru Kilonzo; Lindsey Te Brake; Davis Kibirige; Nyasatu Chamba; Nyanda Elias Ntinginya; Issa Sabi; Julia Critchley; Katrina Sharples; Philip C Hill; Reinout Van Crevel Journal: Clin Infect Dis Date: 2022-04-28 Impact factor: 20.999
Authors: María B Arriaga; Mariana Araújo-Pereira; Beatriz Barreto-Duarte; Betânia Nogueira; Maria Vitória C N S Freire; Artur T L Queiroz; Moreno M S Rodrigues; Michael S Rocha; Alexandra B Souza; Renata Spener-Gomes; Anna Cristina C Carvalho; Marina C Figueiredo; Megan M Turner; Betina Durovni; José R Lapa-E-Silva; Afrânio L Kritski; Solange Cavalcante; Valeria C Rolla; Marcelo Cordeiro-Santos; Timothy R Sterling; Bruno B Andrade Journal: J Infect Dis Date: 2022-02-15 Impact factor: 7.759
Authors: R C Koesoemadinata; S M McAllister; N N M Soetedjo; P Santoso; R Ruslami; H Damayanti; N Rahmadika; B Alisjahbana; R van Crevel; P C Hill Journal: Public Health Action Date: 2021-12-21
Authors: Lauren S Peetluk; Felipe M Ridolfi; Peter F Rebeiro; Dandan Liu; Valeria C Rolla; Timothy R Sterling Journal: BMJ Open Date: 2021-03-02 Impact factor: 2.692
Authors: April C Pettit; Cathy A Jenkins; Meridith Blevins Peratikos; Marcel Yotebieng; Lameck Diero; Cuong D Do; Jeremy Ross; Valdilea G Veloso; Denise Hawerlander; Olivier Marcy; Bryan E Shepherd; Lukas Fenner; Timothy R Sterling Journal: J Int AIDS Soc Date: 2019-12 Impact factor: 5.396
Authors: Roma Sinha; Minh Dao Ngo; Stacey Bartlett; Helle Bielefeldt-Ohmann; Sahar Keshvari; Sumaira Z Hasnain; Meg L Donovan; Jessica C Kling; Antje Blumenthal; Chen Chen; Kirsty R Short; Katharina Ronacher Journal: Front Cell Infect Microbiol Date: 2021-07-06 Impact factor: 6.073
Authors: Susanne F Awad; Peijue Huangfu; Houssein H Ayoub; Fiona Pearson; Soha R Dargham; Julia A Critchley; Laith J Abu-Raddad Journal: J Glob Health Date: 2019-12 Impact factor: 4.413
Authors: Anna Cristina C Carvalho; Gustavo Amorim; Mayla G M Melo; Ana Karla A Silveira; Pedro H L Vargas; Adriana S R Moreira; Michael S Rocha; Alexandra B Souza; María B Arriaga; Mariana Araújo-Pereira; Marina C Figueiredo; Betina Durovni; José R Lapa-E-Silva; Solange Cavalcante; Valeria C Rolla; Timothy R Sterling; Marcelo Cordeiro-Santos; Bruno B Andrade; Elisangela C Silva; Afrânio L Kritski Journal: Front Immunol Date: 2021-07-02 Impact factor: 7.561